Foamix and Menlo Therapeutics have signed a definitive merger agreement to form a biopharmaceutical Company focused on dermatological conditions. The combined entity will have a robust portfolio of diversified candidates, including an approved product and three late-stage clinical candidates. Foamix’s AMZEEQ™ (minocycline) topical foam, 4%, recently...
Rosacea affects over 415 million people worldwide, and more than 16 million in the U.S alone, according to research conducted by the University of Copenhagen, Denmark. It is a fairly common skin disorder, but only 18 percent of Americans afflicted with this condition are under...
Foamix Pharmaceuticals (NASDAQ: FOMX), a clinical stage biotechnology company that is focused on creating solutions for the unmet needs in dermatology by developing topical therapies, has announced that it has secured nearly $64 million in financing from Perceptive Advisors and OrbiMed. According to a company...
Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease such as atopic dermatitis, mycoses, chickenpox, hepatitis, Jaundice, chronic renal failure, cholestasis or NASH. These can be chronic in nature and affect...
